Cargando…
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]
BACKGROUND: Over 2021, COVID-19 vaccination programs worldwide focused on raising population immunity through the primary COVID-19 vaccine series. In Singapore, two mRNA vaccines (BNT162b2 and mRNA-1273) and the inactivated vaccine CoronaVac are currently authorized under the National Vaccination Pr...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201789/ https://www.ncbi.nlm.nih.gov/pubmed/35710572 http://dx.doi.org/10.1186/s13063-022-06345-2 |
_version_ | 1784728390357483520 |
---|---|
author | Poh, Xuan Ying Lee, I. Russel Lim, Clarissa Teo, Jefanie Rao, Suma Chia, Po Ying Ong, Sean W. X. Lee, Tau Hong Lin, Ray J. H. Ng, Lisa F. P. Ren, Ee Chee Lin, Raymond T. P. Wang, Lin-Fa Renia, Laurent Lye, David Chien Young, Barnaby E. |
author_facet | Poh, Xuan Ying Lee, I. Russel Lim, Clarissa Teo, Jefanie Rao, Suma Chia, Po Ying Ong, Sean W. X. Lee, Tau Hong Lin, Ray J. H. Ng, Lisa F. P. Ren, Ee Chee Lin, Raymond T. P. Wang, Lin-Fa Renia, Laurent Lye, David Chien Young, Barnaby E. |
author_sort | Poh, Xuan Ying |
collection | PubMed |
description | BACKGROUND: Over 2021, COVID-19 vaccination programs worldwide focused on raising population immunity through the primary COVID-19 vaccine series. In Singapore, two mRNA vaccines (BNT162b2 and mRNA-1273) and the inactivated vaccine CoronaVac are currently authorized under the National Vaccination Programme for use as the primary vaccination series. More than 90% of the Singapore population has received at least one dose of a COVID-19 vaccine as of December 2021. With the demonstration that vaccine effectiveness wanes in the months after vaccination, and the emergence of Omicron which evades host immunity from prior infection and/or vaccination, attention in many countries has shifted to how best to maintain immunity through booster vaccinations. METHODS: The objectives of this phase 3, randomized, subject-blinded, controlled clinical trial are to assess the safety and immunogenicity of heterologous boost COVID-19 vaccine regimens (intervention groups 1–4) compared with a homologous boost regimen (control arm) in up to 600 adult volunteers. As non-mRNA vaccine candidates may enter the study at different time points depending on vaccine availability and local regulatory approval, participants will be randomized at equal probability to the available intervention arms at the time of randomization. Eligible participants will have received two doses of a homologous mRNA vaccine series with BNT162b2 or mRNA-1273 at least 6 months prior to enrolment. Participants will be excluded if they have a history of confirmed SARS or SARS-CoV-2 infection, are immunocompromised, or are pregnant. Participants will be monitored for adverse events and serious adverse events by physical examinations, laboratory tests and self-reporting. Blood samples will be collected at serial time points [pre-vaccination/screening (day − 14 to day 0), day 7, day 28, day 180, day 360 post-vaccination] for assessment of antibody and cellular immune parameters. Primary endpoint is the level of anti-SARS-CoV-2 spike immunoglobulins at day 28 post-booster and will be measured against wildtype SARS-CoV-2 and variants of concern. Comprehensive immune profiling of the humoral and cellular immune response to vaccination will be performed. DISCUSSION: This study will provide necessary data to understand the quantity, quality, and persistence of the immune response to a homologous and heterologous third booster dose of COVID-19 vaccines. This is an important step in developing COVID-19 vaccination programs beyond the primary series. TRIAL REGISTRATION: ClinicalTrials.govNCT05142319. Registered on 2 Dec 2021. |
format | Online Article Text |
id | pubmed-9201789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-92017892022-06-17 Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC] Poh, Xuan Ying Lee, I. Russel Lim, Clarissa Teo, Jefanie Rao, Suma Chia, Po Ying Ong, Sean W. X. Lee, Tau Hong Lin, Ray J. H. Ng, Lisa F. P. Ren, Ee Chee Lin, Raymond T. P. Wang, Lin-Fa Renia, Laurent Lye, David Chien Young, Barnaby E. Trials Study Protocol BACKGROUND: Over 2021, COVID-19 vaccination programs worldwide focused on raising population immunity through the primary COVID-19 vaccine series. In Singapore, two mRNA vaccines (BNT162b2 and mRNA-1273) and the inactivated vaccine CoronaVac are currently authorized under the National Vaccination Programme for use as the primary vaccination series. More than 90% of the Singapore population has received at least one dose of a COVID-19 vaccine as of December 2021. With the demonstration that vaccine effectiveness wanes in the months after vaccination, and the emergence of Omicron which evades host immunity from prior infection and/or vaccination, attention in many countries has shifted to how best to maintain immunity through booster vaccinations. METHODS: The objectives of this phase 3, randomized, subject-blinded, controlled clinical trial are to assess the safety and immunogenicity of heterologous boost COVID-19 vaccine regimens (intervention groups 1–4) compared with a homologous boost regimen (control arm) in up to 600 adult volunteers. As non-mRNA vaccine candidates may enter the study at different time points depending on vaccine availability and local regulatory approval, participants will be randomized at equal probability to the available intervention arms at the time of randomization. Eligible participants will have received two doses of a homologous mRNA vaccine series with BNT162b2 or mRNA-1273 at least 6 months prior to enrolment. Participants will be excluded if they have a history of confirmed SARS or SARS-CoV-2 infection, are immunocompromised, or are pregnant. Participants will be monitored for adverse events and serious adverse events by physical examinations, laboratory tests and self-reporting. Blood samples will be collected at serial time points [pre-vaccination/screening (day − 14 to day 0), day 7, day 28, day 180, day 360 post-vaccination] for assessment of antibody and cellular immune parameters. Primary endpoint is the level of anti-SARS-CoV-2 spike immunoglobulins at day 28 post-booster and will be measured against wildtype SARS-CoV-2 and variants of concern. Comprehensive immune profiling of the humoral and cellular immune response to vaccination will be performed. DISCUSSION: This study will provide necessary data to understand the quantity, quality, and persistence of the immune response to a homologous and heterologous third booster dose of COVID-19 vaccines. This is an important step in developing COVID-19 vaccination programs beyond the primary series. TRIAL REGISTRATION: ClinicalTrials.govNCT05142319. Registered on 2 Dec 2021. BioMed Central 2022-06-16 /pmc/articles/PMC9201789/ /pubmed/35710572 http://dx.doi.org/10.1186/s13063-022-06345-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Poh, Xuan Ying Lee, I. Russel Lim, Clarissa Teo, Jefanie Rao, Suma Chia, Po Ying Ong, Sean W. X. Lee, Tau Hong Lin, Ray J. H. Ng, Lisa F. P. Ren, Ee Chee Lin, Raymond T. P. Wang, Lin-Fa Renia, Laurent Lye, David Chien Young, Barnaby E. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC] |
title | Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC] |
title_full | Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC] |
title_fullStr | Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC] |
title_full_unstemmed | Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC] |
title_short | Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC] |
title_sort | evaluation of the safety and immunogenicity of different covid-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [pribivac] |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201789/ https://www.ncbi.nlm.nih.gov/pubmed/35710572 http://dx.doi.org/10.1186/s13063-022-06345-2 |
work_keys_str_mv | AT pohxuanying evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT leeirussel evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT limclarissa evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT teojefanie evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT raosuma evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT chiapoying evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT ongseanwx evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT leetauhong evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT linrayjh evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT nglisafp evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT reneechee evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT linraymondtp evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT wanglinfa evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT renialaurent evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT lyedavidchien evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac AT youngbarnabye evaluationofthesafetyandimmunogenicityofdifferentcovid19vaccinecombinationsinhealthyindividualsstudyprotocolforarandomizedsubjectblindedcontrolledphase3trialpribivac |